| ORIGINAL ARTICLE |
|
| Year : 2015 | Volume
: 2
| Issue : 1 | Page : 14-18 |
|
|
Clinical practice guidance for the use of clomiphene citrate in Male Hormone Replacement Therapy (HRT)
Michael A. S Guth
Senior Director, Health Economics & Outcomes Research, Risk Management Consulting, Oak Ridge, Tennessee, U.S.A
Correspondence Address:
Michael A. S Guth
116 Oklahoma Ave, Oak Ridge, TN, 37830-8604
U.S.A
 Source of Support: None, Conflict of Interest: None
DOI: 10.5530/ami.2015.1.4
|
|
|
Introduction: Inhibition of pituitary gonadotropin secretion in men by testosterone (T) is principally mediated by aromatization to estrogen (E), which inhibits hypothalamic secretion of gonadotropin-releasing hormone (GnRH). Material and Methods: Longitudinal clinical investigation unit-based evaluation of the clinical and biochemical response to E-receptor blockade. Initial monotherapy with 50 mg of clomiphene citrate (CC) daily for a period of 9 months, with diurnal morning peak testosterone and luteinizing hormone (LH) levels evaluated at three-month intervals thereafter. The patient then resumed hormone replacement therapy (HRT) using T cream with adjuvant CC therapy. Main Outcome Measures were Baseline and stimulated T and LH levels; effect on sexual function. Result(S): CC therapy resulted in complete normalization of pulsatile gonadotropin secretion, serum T level, and sexual function. Conclusion(S): Isolated hypogonadotropic hypogonadism (IHH) may result from an acquired defect of enhanced hypothalamic sensitivity to E-mediated negative feedback. Whereas direct T replacement therapy can further suppress endogenous gonadotropin secretion, treating IHH men with gonadotropins can stimulate endogenous T secretion and enhance fertility potential. Reversal of gonadotropin deficiency with CC was found to have a similar biological effect.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
